Epoetin Administration for Dialysis Patients with Anemia

Initial Dosing Recommendations

The National Kidney Foundation guidelines recommend initiating epoetin at 120-180 units/kg/week, given in three divided doses, for hemodialysis patients receiving intravenous epoetin 1
A starting dose of 4000 units three times weekly falls within the recommended range for most adult patients, according to the American Journal of Kidney Diseases 2, 3
The National Kidney Foundation guidelines recommend administering epoetin in divided doses during each dialysis treatment when using the IV route 2
When given intravenously, epoetin should be injected into either the arterial or venous blood lines at any time during the hemodialysis procedure, as recommended by the American Journal of Kidney Diseases 3

Subcutaneous administration is generally more efficient than IV administration, requiring 15-50% lower doses to maintain target hemoglobin levels, according to the American Journal of Kidney Diseases 4, 5
For patients who cannot tolerate SC administration, IV administration during dialysis is appropriate, as stated by the American Journal of Kidney Diseases 3, 6
When using IV administration, the weekly dose should be given in divided doses during each dialysis treatment, to avoid a lower hemoglobin response and increased epoetin requirements, as recommended by the American Journal of Kidney Diseases 2, 3

Hemoglobin/hematocrit should be measured every 1-2 weeks following initiation of treatment to monitor response, according to the American Journal of Kidney Diseases 7, 8
With optimal iron stores, the expected rise in hemoglobin is approximately 0.3 g/dL per week, as stated by the American Journal of Kidney Diseases 8
If the hemoglobin increase is less than 2 percentage points over 2-4 weeks, the dose should be increased by 50%, as recommended by the American Journal of Kidney Diseases 7, 8
If the hemoglobin increases by more than 3 g/dL per month, the weekly dose should be reduced by 25%, according to the American Journal of Kidney Diseases 7, 8

Iron status should be evaluated before and during epoetin treatment, as recommended by the National Kidney Foundation 9
The most common cause of an incomplete response to epoetin is iron deficiency, according to the American Journal of Kidney Diseases 2
Iron supplementation should aim to maintain transferrin saturation >20% and serum ferritin >100 μg/L, as stated by the National Kidney Foundation 9

Avoid injecting epoetin into the venous drip chamber of the Fresenius delivery system, as this can result in "trapping" and incomplete mixing with the patient's blood, as warned by the American Journal of Kidney Diseases 2, 3
For patients with significant intercurrent illness or who undergo surgery, the erythropoietic response to epoetin may be reduced, according to the American Journal of Kidney Diseases 3, 6
Be aware that 96% of patients will respond to epoetin at appropriate doses within 4-6 months, provided there are adequate iron stores, as stated by the American Journal of Kidney Diseases 2